|
DSP Healthcare Fund An open ended equity scheme investing in healthcare and pharmaceutical sector |
|
|
Aditya Khemka
Total work experience of 11 years.
Managing this Scheme since
November 2018.
Vinit Sambre
Total work experience of 19 years.
Managing this Scheme since
November 2018.
Jay Kothari (Dedicated Fund
Manager for overseas investments)
Total work experience of 14 years.
Managing this Scheme since
November 2018.
Nov 30, 2018
S&P BSE HEALTHCARE (TRI)
| Regular Plan | |
| Growth: | ₹ 11.873 |
| Direct Plan | |
| Growth: | ₹ 12.143 |
₹ 291 Cr
₹ 290 Cr
0.15
| Regular Plan : | 2.48% |
| Direct Plan : | 0.22% |
Holding period <12 months: 1%
Holding period >=12 months: Nil
| Name of Instrument | % to Net Assets |
| EQUITY & EQUITY RELATED | |
| Listed / awaiting listing on the stock exchanges | |
| Pharmaceuticals | 73.32% |
| ✔ IPCA Laboratories Limited | 9.65% |
| ✔ Dr. Reddy's Laboratories Limited | 8.87% |
| ✔ Divi's Laboratories Limited | 7.55% |
| ✔ JB Chemicals & Pharmaceuticals Limited | 7.35% |
| ✔ Indoco Remedies Limited | 5.40% |
| ✔ Sun Pharmaceutical Industries Limited | 4.42% |
| ✔ Abbott India Limited | 3.41% |
| ✔ Torrent Pharmaceuticals Limited | 3.37% |
| Jubilant Life Sciences Limited | 3.27% |
| Ajanta Pharma Limited | 3.15% |
| Alkem Laboratories Limited | 3.12% |
| Alembic Pharmaceuticals Limited | 3.11% |
| Syngene International Limited | 2.96% |
| Procter & Gamble Health Limited | 2.85% |
| Aarti Drugs Limited | 2.84% |
| Unichem Laboratories Limited | 2.00% |
| healthcare Services | 14.60% |
| ✔ Apollo Hospitals Enterprise Limited | 5.89% |
| ✔ Max India Limited | 3.66% |
| Narayana Hrudayalaya Ltd. | 2.59% |
| Dr. Lal Path Labs Ltd. | 2.45% |
| Finance | 1.17% |
| ICICI Lombard General Insurance Company Limited | 1.17% |
| Total | 89.08% |
| Foreign Securities and/or overseas ETF(s) | |
| Listed / awaiting listing on the stock exchanges | |
| Pharmaceuticals | 3.17% |
| Abbott Laboratories | 3.17% |
| healthcare Services | 2.42% |
| Abiomed Inc | 2.42% |
| Total | 5.59% |
| MONEY MARKET INSTRUMENTS | |
| TREPS / Reverse Repo Investments / Corporate Debt Repo | 5.08% |
| Total | 5.08% |
| Cash & Cash Equivalent | |
| Net Receivables/Payables | 0.25% |
| Total | 0.25% |
| GRAND TOTAL | 100.00% |
✔ Top Ten Holdings
| Positions Increased |
| Stock |
| Healthcare Services |
| Dr. Lal Path Labs Ltd. |
Rebalances below 0.05 % are not considered.
The primary investment objective of the
scheme is to seek to generate consistent
returns by predominantly investing in
equity and equity related securities of
pharmaceutical and healthcare companies.
However, there can be no assurance that
the investment objective of the scheme will
be realized.
This open ended equity Scheme is suitable for investors who are seeking*
• Long term capital growth
• Investment in equity and equity related Securities of healthcare and pharmaceutical companies
* Investors should consult their financial advisors if in doubt whether the product is suitable for them.